Posts Tagged ‘obesity treatment’
March 18, 2024 — Hear that rumble? Nope, it not the latest SpaceX launch. It is the roar of growing demand for obesity care in the U.S. Two pieces of news in the last week remind us of how steep the upward line of growth in obesity treatment is right now. To help it scale up their reach to […]
March 15, 2024 — Prior authorizations are a driving force in the burnout of physicians, denial of medical care, and the profitability of health insurance and pharmacy benefit plans. By one estimate, healthcare providers spend $35 billion every year on chasing down prior authorizations so that their patients can receive the care they need – whether that is a […]
March 13, 2024 — The drug development pipeline is filling up with new new drugs for weight loss or obesity. On Thursday, Novo Nordisk caused the hearts of investors to flutter when it presented topline results on an oral medicine that might be more effective than semaglutide. The value of the company’s stock jumped by 13%. Just a week […]
March 10, 2024 — For many of us, it’s just too painful to think about. But a rerun of the 2020 presidential election is coming and drug pricing is likely to be a big talking point for both of the major candidates. President Biden is talking about corporate greed while former President Trump is talking about reviving an executive […]
March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]
March 7, 2024 — Obesity Care Week this year comes at a time when we have shiny new tools for treating obesity that are garnering a whole lot of attention. One would have be living under a rock not to have heard all the buzz about semaglutide, tirzepatide, and a host of other medicines coming soon for obesity. But […]
March 5, 2024 — On this, the second day of Obesity Care Week, let’s step back from all the complexity of obesity and focus on five simple principles that hold great promise for improving the way we care for people with this disease. It really doesn’t have to be so hard. 1. It Is Undeniable That Obesity Is a […]
March 4, 2024 — Today marks the start of Obesity Care Week and all over the globe, this is World Obesity Day. To mark this day, dozens of advocates from all of the major organizations that care about improving the standard of care for obesity have converged on the U.S. Capitol for dialog with policymakers about opening the pathway […]
March 1, 2024 — In a new cohort study, it is plain to see that, even before the advent of new GLP-1 medicines for obesity, primary care patients could get better health from obesity care. But health systems hindering delivery of obesity care make this exceedingly unlikely for most people living this disease. A Large Cohort Study from an […]
February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]